| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | Minjuvi | |
| 3 | Generic | tafasitamab | |
| 4 | Indication | DLBCL | |
| 5 | MOA | CD19 | |
| 6 | Economics | Morphosys, originally Xencor license | |
| 7 | Clinical Trials | ||
| 8 | Phase III "inMIND" FL/MZL with lenalidomide | ||
| 9 | |||
| 10 | |||
| 11 | Phase II "L-MIND" DLBCL | ||
| 12 | |||
| 13 | |||
| 14 | Phase III "B-MIND" DLBCL | ||
| 15 | |||
| 16 | |||
| 17 | Phase III "frontMIND" 1L DLBCL | ||
| 18 | |||
| 19 | topMIND |